SOUTH SAN FRANCISCO, Calif., Oct. 20 /PRNewswire-FirstCall/ -- Cell
Genesys, Inc. (Nasdaq: CEGE) today confirmed that new clinical data from both
its GVAX(R) Vaccine for Pancreatic Cancer and GVAX(R) Vaccine for Leukemia
programs will be presented at two upcoming medical conferences later this
year. Following is the schedule of presentations:
-- AACR-NCI-EORTC meeting in Philadelphia, PA, November 17, 2005
Phase 2 Trial of GVAX(R) Vaccine for Pancreatic Cancer
-- American Society of Hematology (ASH) meeting in Atlanta, GA,
December 12, 2005
Phase 2 Trial of GVAX(R) Leukemia Vaccine in Chronic Myelogenous
Leukemia
In other news, Cell Genesys confirmed that it will announce financial
results for the third quarter 2005 after the markets close on Wednesday,
November 2, 2005, and will hold a webcast teleconference on Thursday, November
3, 2005 at 8:30 a.m. PT. Stephen A. Sherwin, M.D., chairman and chief
executive officer, and Sharon E. Tetlow, chief financial officer of Cell
Genesys, will review financial results and events from the third quarter.
The live audio webcast will be available on the investor relations section
of the company's website, http://www.cellgenesys.com. If you are unable to listen to
the live webcast, the call will be archived on the website for at least 48
hours following the call. To access the replay, go to the Investor Relations
section of the website.
Cell Genesys is focused on the development and commercialization of novel
biological therapies for patients with cancer. The company is currently
pursuing two clinical stage product platforms -- GVAX(R) cancer vaccines and
oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of
GVAX(R) vaccine for prostate cancer, Phase 2 trials of GVAX(R) vaccines for
leukemia and pancreatic cancer, and a Phase 1 trial of CG0070 oncolytic virus
therapy for bladder cancer and potentially other types of cancer. Cell Genesys
continues to hold equity interests in its two former subsidiaries -- Abgenix,
Inc., an antibody products company and Ceregene, Inc., which is developing
gene therapies for neurodegenerative disorders. Cell Genesys is headquartered
in South San Francisco, CA and has its principal manufacturing operation in
Hayward, CA. For additional information, please visit the company's website at
http://www.cellgenesys.com.
Statements made herein about the company, other than statements of
historical fact, including statements about the company's progress, results
and timing of clinical trials and preclinical programs and the nature of
product pipelines are forward-looking statements and are subject to a number
of uncertainties that could cause actual results to differ materially from the
statements made, including risks associated with the success of clinical
trials and research and development programs, the regulatory approval process
for clinical trials, competitive technologies and products, patents,
continuation of corporate partnerships and the need for additional financings.
For information about these and other risks which may affect Cell Genesys,
please see the company's Annual Report on Form 10-K for the year ended
December 31, 2004 dated March 14, 2005 as well as Cell Genesys' reports on
Form 10-Q and 8-K and other reports filed from time to time with the
Securities and Exchange Commission. The company assumes no obligation to
update the forward-looking information in this press release.
CONTACT:
Ina Cu
Investor Relations
650-266-3200
SOURCE Cell Genesys, Inc.
 back to top
Related links:
http://www.cellgenesys.com
CONTACT:
Ina Cu, Investor Relations, of Cell Genesys,
Inc., +1-650-266-3200
|
